BR112022010561A2 - Compostos poli-heterocíclicos como inibidores de mettl3 - Google Patents

Compostos poli-heterocíclicos como inibidores de mettl3

Info

Publication number
BR112022010561A2
BR112022010561A2 BR112022010561A BR112022010561A BR112022010561A2 BR 112022010561 A2 BR112022010561 A2 BR 112022010561A2 BR 112022010561 A BR112022010561 A BR 112022010561A BR 112022010561 A BR112022010561 A BR 112022010561A BR 112022010561 A2 BR112022010561 A2 BR 112022010561A2
Authority
BR
Brazil
Prior art keywords
mettl3
inhibitors
compounds
polyheterocyclic compounds
relates
Prior art date
Application number
BR112022010561A
Other languages
English (en)
Inventor
Peter Blackaby Wesley
James Hardick David
Jane Thomas Elizabeth
Arthur Brookfield Frederick
Shepherd Jon
Bubert Christian
Peter Ridgill Mark
Original Assignee
Storm Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917603.1A external-priority patent/GB201917603D0/en
Priority claimed from GBGB2015692.3A external-priority patent/GB202015692D0/en
Priority claimed from GBGB2015820.0A external-priority patent/GB202015820D0/en
Application filed by Storm Therapeutics Ltd filed Critical Storm Therapeutics Ltd
Publication of BR112022010561A2 publication Critical patent/BR112022010561A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS POLI-HETEROCÍCLICOS COMO INIBIDORES DE METTL3. A presente invenção refere-se a compostos de fórmula (I) que atuam como inibidores da atividade enzimática de METTL3 (subunidade de 70 kDa da N6-adenosina-metiltransferase): X-Y-Z [I], em que X, Y e Z são, cada um, como definidos neste documento. A presente invenção também se refere a processos para a preparação desses compostos, a composições farmacêuticas que os compreendem e ao seu uso no tratamento de transtornos proliferativos, como câncer, e doenças autoimunes, bem como outras doenças ou condições nas quais a atividade de METTL3 está implicada.
BR112022010561A 2019-12-02 2020-12-01 Compostos poli-heterocíclicos como inibidores de mettl3 BR112022010561A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1917603.1A GB201917603D0 (en) 2019-12-02 2019-12-02 Inhibitory compounds
GBGB2015692.3A GB202015692D0 (en) 2020-10-02 2020-10-02 Inhibitory compounds
GBGB2015820.0A GB202015820D0 (en) 2020-10-06 2020-10-06 Inhibitory compounds
PCT/GB2020/053081 WO2021111124A1 (en) 2019-12-02 2020-12-01 Polyheterocyclic compounds as mettl3 inhibitors

Publications (1)

Publication Number Publication Date
BR112022010561A2 true BR112022010561A2 (pt) 2022-11-16

Family

ID=73854829

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010561A BR112022010561A2 (pt) 2019-12-02 2020-12-01 Compostos poli-heterocíclicos como inibidores de mettl3

Country Status (11)

Country Link
US (2) US20230116403A1 (pt)
EP (1) EP4069694A1 (pt)
JP (1) JP2023506147A (pt)
KR (1) KR20220113431A (pt)
CN (1) CN115151540A (pt)
AU (1) AU2020394867A1 (pt)
BR (1) BR112022010561A2 (pt)
CA (1) CA3162166A1 (pt)
IL (1) IL293340A (pt)
MX (1) MX2022006700A (pt)
WO (1) WO2021111124A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
WO2022074379A1 (en) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
CN115894447A (zh) * 2021-09-22 2023-04-04 成都先导药物开发股份有限公司 Mettl3抑制剂及其用途
CN116514805A (zh) * 2021-12-10 2023-08-01 成都先导药物开发股份有限公司 Mettl3抑制剂化合物
WO2023129933A2 (en) * 2021-12-29 2023-07-06 858 Therapeutics, Inc. 6,6-fused heterocyclic compounds as mettl3 inhibitors
WO2023151697A1 (zh) * 2022-02-11 2023-08-17 四川海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
WO2023235756A1 (en) * 2022-05-31 2023-12-07 The Trustees Of The University Of Pennsylvania Compounds for the treatment of hiv
WO2024056099A1 (zh) * 2022-09-16 2024-03-21 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734814B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
US5928323A (en) 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AR012117A1 (es) 1997-03-21 2000-09-27 Novartis Ag Compuestos herbicidas, proceso para su preparacion, compuestos intermediarios para su exclusivo uso en dicho proceso, composicion herbicidae inhibidora del crecimiento de las plantas, metodo para controlar el crecimiento indeseado de plantas y uso de dicha composicion en el control de
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
HUP0302526A2 (hu) 2000-12-21 2003-11-28 Glaxo Group Limited Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
MX2007015772A (es) 2005-06-17 2008-02-22 Wyeth Corp Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a.
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
DE602006012535D1 (de) 2005-10-21 2010-04-08 Glaxo Group Ltd Peri-kondensierte tricyclische verbindungen verwendbar als antibakterielle mittel
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
WO2008016666A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
KR20100049698A (ko) 2006-12-22 2010-05-12 아벡사 리미티드 바이사이클 피리미디논 및 그 용도
AU2008216789A1 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
WO2009127678A1 (en) * 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
US8431581B2 (en) 2008-07-02 2013-04-30 Avexa Limited Imidazopyrimidines and uses thereof
CA2729663A1 (en) 2008-07-02 2010-01-07 Avexa Limited Compounds having antiviral properties
CA2729649A1 (en) 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
TW201100424A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
WO2010138600A2 (en) * 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN102336751A (zh) 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
SG10201707548RA (en) 2013-03-19 2017-10-30 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
JP6386177B2 (ja) 2014-06-17 2018-09-05 ツーセン ファーマシューティカル カンパニー リミテッド ｍＴＯＲ／ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミジノン類似体
ES2754264T3 (es) 2014-06-17 2020-04-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K
EA031589B1 (ru) 2014-08-22 2019-01-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018098446A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Methods for modulating rna splicing
WO2018183145A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
EP3589745A1 (en) * 2018-04-11 2020-01-08 Chemestmed Ltd. A method of modulating the rna methylation
CN112585119A (zh) 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
MX2021006347A (es) 2018-11-30 2021-10-13 Epizyme Inc Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
EP3946618A1 (en) * 2019-04-05 2022-02-09 Storm Therapeutics Ltd Mettl3 inhibitory compounds
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物

Also Published As

Publication number Publication date
WO2021111124A1 (en) 2021-06-10
US20230002378A1 (en) 2023-01-05
EP4069694A1 (en) 2022-10-12
CA3162166A1 (en) 2021-06-10
US20230116403A1 (en) 2023-04-13
KR20220113431A (ko) 2022-08-12
MX2022006700A (es) 2022-09-02
JP2023506147A (ja) 2023-02-15
AU2020394867A1 (en) 2022-05-26
CN115151540A (zh) 2022-10-04
US11725010B2 (en) 2023-08-15
IL293340A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
BR112022010561A2 (pt) Compostos poli-heterocíclicos como inibidores de mettl3
BR112018071097A2 (pt) compostos heterocíclicos como inibidores de ret cinase
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112012020693A8 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
BR112015014701B8 (pt) Derivados de benzimidazol e seus usos
BR112017012402A2 (pt) derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112014029310A2 (pt) análogos da pirimidina heterocíclica como inibidores da tyk2
BR112014015723A8 (pt) derivados de pirimidino-2,4-diamina como inibidores da quinase
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação